OTCMKTS:ARGSQ - Argos Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.08 0.00 (0.00 %)
(As of 04/24/2019 04:12 AM ET)
Previous Close$0.08
Today's Range$0.0640 - $0.08
52-Week Range$0.0190 - $0.3025
Volume10,538 shs
Average Volume16,838 shs
Market Capitalization$846,960.00
P/E RatioN/A
Dividend YieldN/A
Beta3.39
Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on its proprietary technology platform, Arcelis. Its product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma. The company also develops AGS-004, which is in Phase II clinical trials for the treatment of human immunodeficiency virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is based in Durham, North Carolina. As of February 13, 2019, Argos Therapeutics Inc. operates as a subsidiary of Genexine Inc. and SCM Lifescience Co.

Receive ARGSQ News and Ratings via Email

Sign-up to receive the latest news and ratings for ARGSQ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ARGSQ
CUSIPN/A
Phone919-287-6300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.90 million
Book Value($1.63) per share

Profitability

Net Income$-40,570,000.00
Net Margins-173.88%

Miscellaneous

Employees21
Market Cap$846,960.00
Next Earnings Date5/21/2019 (Estimated)
OptionableNot Optionable

Argos Therapeutics (OTCMKTS:ARGSQ) Frequently Asked Questions

What is Argos Therapeutics' stock symbol?

Argos Therapeutics trades on the OTCMKTS under the ticker symbol "ARGSQ."

When did Argos Therapeutics' stock split? How did Argos Therapeutics' stock split work?

Argos Therapeutics shares reverse split before market open on Friday, January 19th 2018. The 1-20 reverse split was announced on Thursday, January 18th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 18th 2018. An investor that had 100 shares of Argos Therapeutics stock prior to the reverse split would have 5 shares after the split.

How were Argos Therapeutics' earnings last quarter?

Argos Therapeutics Inc (OTCMKTS:ARGSQ) issued its quarterly earnings results on Wednesday, August, 9th. The biopharmaceutical company reported ($4.20) earnings per share for the quarter, topping analysts' consensus estimates of ($4.50) by $0.30. The biopharmaceutical company earned $0.07 million during the quarter, compared to analysts' expectations of $0.10 million. View Argos Therapeutics' Earnings History.

When is Argos Therapeutics' next earnings date?

Argos Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, May 21st 2019. View Earnings Estimates for Argos Therapeutics.

Has Argos Therapeutics been receiving favorable news coverage?

News headlines about ARGSQ stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Argos Therapeutics earned a media sentiment score of 1.6 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future.

Who are some of Argos Therapeutics' key competitors?

What other stocks do shareholders of Argos Therapeutics own?

Who are Argos Therapeutics' key executives?

Argos Therapeutics' management team includes the folowing people:
  • Dr. Charles A. Nicolette, Consultant (Age 57)
  • Mr. Jeffrey D. Abbey, Consultant & Director (Age 57)
  • Dr. Richard D. Katz, Consultant (Age 55)
  • Mr. William N. Wofford, Sec.
  • Ms. Lori R. Harrelson CPA, CPA, VP of Fin. (Age 50)

How do I buy shares of Argos Therapeutics?

Shares of ARGSQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Argos Therapeutics' stock price today?

One share of ARGSQ stock can currently be purchased for approximately $0.08.

How big of a company is Argos Therapeutics?

Argos Therapeutics has a market capitalization of $846,960.00 and generates $1.90 million in revenue each year. Argos Therapeutics employs 21 workers across the globe.

What is Argos Therapeutics' official website?

The official website for Argos Therapeutics is http://www.argostherapeutics.com.

How can I contact Argos Therapeutics?

Argos Therapeutics' mailing address is 4233 TECHNOLOGY DR, DURHAM NC, 27704. The biopharmaceutical company can be reached via phone at 919-287-6300.


MarketBeat Community Rating for Argos Therapeutics (OTCMKTS ARGSQ)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  277 (Vote Outperform)
Underperform Votes:  174 (Vote Underperform)
Total Votes:  451
MarketBeat's community ratings are surveys of what our community members think about Argos Therapeutics and other stocks. Vote "Outperform" if you believe ARGSQ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARGSQ will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel